¹²⁹Xe(XENON) MRI Program

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-85
SponsorAlexei Ouriadov

About this trial

Healthy volunteers aged 18 to 85 will undergo hyperpolarized Xenon-129 (¹²⁹Xe) MRI and pulmonary function testing. The study aims to develop evaluation tools for ventilation defect percent (VDP), signal-to-noise and contrast-to-noise ratios (SNR/CNR) of ¹²⁹Xe dissolved-phase images, and spectroscopy-based analysis.

Eligibility criteria

Qualifiers

Patient understands study procedures and is willing to participate in the study as indicated by the patient's signature.

Provision of written, informed consent prior to any study specific procedures.

Males and females aged 18 to 85 years.

Participant must be able to perform a breath-hold for 16s.

Disqualifiers

Patient has an MR incompatible implanted mechanically, electrically, or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and/or ear implants) (at the discretion of the MRI Technologist).

In the investigator's opinion, subject suffers from any physical, psychological or other condition(s) that might prevent performance of the MRI or CT, such as severe claustrophobia.

Participants who are pregnant, breastfeeding or have a positive pregnancy test at initial screening visit.

Participant is unable to perform spirometry maneuvers.

Trial design

Treatments tested in this trial

  • Hyperpolarized Xenon MRI

Treatment groups

200 Participants
are divided into 1 treatment group

Sponsors and collaborators

Alexei Ouriadov

Lead sponsor

Western University

Sponsor institution

St. Joseph's Health Care London

Collaborator